ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) announced today that its Chief Commercial
Officer, Peter Melnyk, will be leaving the company to pursue other
interests. Mr. Melnyk will continue his employment with the company
until March 15, 2017 to ensure a smooth transition.
"I want to thank Peter for his more than five years of leadership at
Novocure. During his tenure, Peter developed our commercial business
model, launched the Optune brand and drove eight consecutive quarters of
active patient and revenue growth after the presentation of our EF-14
clinical data in Q4 2014. Peter leaves our commercial organization in a
strong position to continue its success,” said Asaf Danziger, Novocure’s
Chief Executive Officer. “I look forward to following Peter’s continued
accomplishments as he begins the next chapter of his career.”
Upon Mr. Melnyk’s departure, Pritesh Shah, Senior Vice President of the
Americas, Thomas Hefti, Vice President of Europe and Emerging Markets,
and Shungo Matori, General Manager of Japan, will report directly to Mr.
Danziger.
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment centered on a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating TTFields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Haifa, Israel. For additional information about the company,
please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170223005354/en/
Source: Novocure